$BLLN News

BillionToOne - Starting 2026 Strong

Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $120

Wall Street Analysts Predict a 25.63% Upside in BillionToOne (BLLN): Here's What You Should Know

JP Morgan Maintains Overweight on BillionToOne, Raises Price Target to $125

BTIG Maintains Buy on BillionToOne, Lowers Price Target to $130

Billiontoone Q1 Earnings Call Highlights

BillionToOne (NASDAQ:BLLN) Blows Past Q1 Estimates, Raises Full-Year Outlook

BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say

BillionToOne (BLLN) Q1 2026 Earnings Transcript

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

BillionToOne Raises FY2026 Sales Guidance from $430.000M-$445.000M to $450.000M-$465.000M vs $437.597M Est

BillionToOne Q2 EPS $0.34 Beats $0.04 Estimate, Sales $108.388M Beat $96.885M Estimate

What Makes BillionToOne (BLLN) a Revolutionizer in Genetic Testing?

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

Guggenheim Maintains Buy on BillionToOne, Lowers Price Target to $100

BillionToOne Medicare Win Puts North Star Economics In Focus

BillionToOne, Inc. 2025 Q4 - Results - Earnings Call Presentation

BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript